Compounded Semaglutide or Tirzepatide injections are customized weight loss treatments that combine Semaglutide or Tirzepatide with additional vitamins, such as B12, tailored to meet individual patient needs. These compounded versions can serve as alternatives to FDA-approved Semaglutide or Tirzepatide during medication shortages. Compounded medications are legally produced by pharmacies adhering to FDA guidelines.

At Peace and Heart Mind Care and Peace and Heart Wellness, exclusively source compounded medications from reputable, state-licensed pharmacies or FDA-registered facilities. Due to unprecedented demand and subsequent shortages of injectable forms like Ozempic and Wegovy, pharmacies have begun creating compounded versions. While no generic form of Semaglutide exists, compounding involves combining, mixing, or altering ingredients to produce the medication for individual patients when necessary.

There are important safety warnings and guidelines for using Semaglutide/Tirzepatide, which include cautionary advice about pancreatitis, gallstones (cholelithiasis), gallbladder inflammation (cholecystitis), thyroid conditions, changes in heart rate, dehydration, and low blood sugar in people with type 2 diabetes. Particularly, those with existing thyroid conditions should use Semaglutide/Tirzepatide cautiously due to reports of thyroid-related adverse effects, such as goiter. Patients using Semaglutide/Tirzepatide have shown an increased incidence of gallstones and gallbladder disease, which can sometimes require hospitalization or surgery to remove the gallbladder. It's vital for patients to recognize the symptoms related to gallstones and gallbladder inflammation. Dehydration signs and symptoms, including kidney impairment and acute kidney failure, have been noted in individuals treated with Semaglutide/Tirzepatide. Hence, patients are advised to stay hydrated, especially considering the gastrointestinal side effects that might contribute to fluid loss. Awareness of symptoms related to an increase in heart rate is also advised. Instances of acute pancreatitis have been associated with Semaglutide/Tirzepatide. If pancreatitis is suspected, discontinuation of the medication is advised; if confirmed, reinitiation of the treatment should not occur. Concerning thyroid C-cell tumors, studies in rats and mice at clinically relevant exposures have shown Semaglutide/Tirzepatide may cause such tumors in both genders. Whether Semaglutide/Tirzepatide can cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) in humans, remains unconfirmed due to the uncertain relevance of these findings to humans. Symptoms of thyroid tumors, such as neck masses, swallowing difficulties, breathing issues, or persistent hoarseness, should be monitored. Additionally, there is a risk of gastroparesis (stomach paralysis) because of delayed gastric emptying. Common side effects include nausea, constipation, decreased appetite, dizziness, low blood sugar, vomiting, indigestion, abdominal pain, diarrhea, headaches, fatigue, and increased levels of lipase. Nausea is notably common at the start of treatment but tends to decrease as the body adjusts to the medication. The dosing schedule is structured to minimize gastrointestinal discomfort. Any side effects that are bothersome or persistent should be reported to a healthcare professional. Risks of treatment with Semaglutide/Tirzepatide not limited to but include common or very common effects such as altered taste, dry mouth, insomnia, weakness, burping, constipation, diarrhea, dizziness, gallbladder issues, gastrointestinal discomfort and disorders, insomnia, nausea, vomiting, hypoglycemia, indigestion, gastritis, gastroesophageal reflux disease, flatulence, belching, upper abdominal pain, abdominal distension, gallstones, injection site reactions, fatigue, and increased levels of lipase and amylase. Less common effects include general discomfort, pancreatitis, rapid heartbeat, and hives; rare effects include kidney impairment, allergic reactions, and anaphylaxis.